We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Kromek Group Plc | LSE:KMK | London | Ordinary Share | GB00BD7V5D43 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.40 | 5.84% | 7.25 | 1,554,889 | 16:18:08 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 7.00 | 7.50 | 7.25 | 6.85 | 6.85 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Miscellaneous Metal Ores,nec | 17.31M | -6.1M | -0.0102 | -7.11 | 43.52M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:07:43 | O | 25,000 | 7.25 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 03/4/2024 | 15:13 | UK RNS | Kromek Group PLC Director/PDMR Shareholding |
| 26/3/2024 | 15:39 | ALNC |  TRADING UPDATES: BATM Advanced ink USD2.3 million orders |
| 26/3/2024 | 07:00 | UK RNS | Kromek Group PLC Kromek receives $2.1m security screening order |
| 06/3/2024 | 15:21 | UK RNS | Kromek Group PLC Holding(s) in Company |
| 04/3/2024 | 12:16 | UK RNS | Kromek Group PLC Holding(s) in Company |
| 04/3/2024 | 11:51 | UK RNS | Kromek Group PLC Result of General Meeting |
| 12/2/2024 | 19:44 | ALNC | TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up |
| 12/2/2024 | 07:00 | UK RNS | Kromek Group PLC Cancellation of £1.2m of Convertible Loan Notes |
| 05/2/2024 | 21:10 | ALNC | TRADING UPDATES: Beowulf appoints project director; Kromek firms grant |
| 05/2/2024 | 10:17 | UK RNS | Kromek Group PLC Conversion of £1.5m of Convertible Loan Notes |
Kromek (KMK) Share Charts1 Year Kromek Chart |
|
1 Month Kromek Chart |
Intraday Kromek Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 21/3/2024 | 09:48 | Kromek Group PLC | 7,098 |
| 05/1/2022 | 09:19 | Kromek Group (KMK) - Overvalued AIM mugging | 182 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-19 16:07:43 | 7.25 | 25,000 | 1,812.50 | O |
| 2024-04-19 15:18:08 | 7.00 | 500 | 35.00 | O |
| 2024-04-19 15:15:04 | 7.23 | 63,000 | 4,557.42 | O |
| Top Posts |
|---|
Posted at 20/4/2024 09:20 by Kromek Daily Update Kromek Group Plc is listed in the Miscellaneous Metal Ores,nec sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 6.85p.Kromek currently has 600,247,000 shares in issue. The market capitalisation of Kromek is £43,517,908. Kromek has a price to earnings ratio (PE ratio) of -7.11. This morning KMK shares opened at 6.85p |
Posted at 09/3/2024 07:49 by croasdalelfc Polymer had 57m when the new loan was announced - now they have 84m which is the rest of the shares from CLNPolymer now has a material interest with 84m with 13% and are owed £5.5m by KMK |
Posted at 06/2/2024 04:08 by riskybisky Proactive interviewKromek Group's positive trajectory Last updated: 09:45 03 Feb 2024 GMT First Published: 09:37 03 Feb 2024 GMT Written by: Ian Lyall Chatting with Proactive's Stephen Gunnion, Kromek Group PLC (AIM:KMK) CEO Arnab Basu shared an optimistic outlook on the company's first-half financial and operational achievements. With a spotlight on increased revenue, improved gross margins and a notably reduced loss, Basu's insights offer a glimpse into the strategic directions propelling Kromek towards sustained growth. Stephen Gunnion (SG): Arnab, Kromek's interim results indicate a strong first half with notable financial improvements. Can you elaborate on these achievements? Arnab Basu (AB): Absolutely, Stephen. We've experienced a period of positive momentum, underpinned by a significant improvement in our EBITDA position and reduced pre-tax losses. This success stems from our unwavering focus on profitability, achieved through diligent cost control and enhancing our business margins. Our growth has been particularly robust in the advanced imaging and CBRN segments, reflecting our alignment with market demands and our strategic initiatives in these areas. SG: Could you dive deeper into the growth drivers within your main business segments? AB: Certainly. Our advanced imaging segment, especially in SPECT and CT modalities, has seen increasing adoption of our CZT material, revolutionizing digital spectrums and enhancing diagnostic capabilities. This trend is underscored by new product launches and significant partnerships, such as our collaboration with a CT Original Equipment Manufacturer (OEM) and Spectrum Dynamics' launch of a new product. On the CBRN front, global security concerns have spiked demand for our handheld radiation detection tools. Our contract wins and robust pipelines in this segment, alongside partnerships for biosecurity projects with the US and UK governments, mark our strategic advancements and readiness to meet evolving market needs. SG: With the momentum built in the first half, how do you anticipate this will impact Kromek's performance moving into the full year 2024? AB: The trajectory we've set in the first half is expected to continue, with the second half traditionally being stronger for us. We're on track to achieve record revenues, a testament to our growth strategy's effectiveness. Our focus remains on cost control and margin improvement, positioning us to report not only significant revenue growth but also a positive EBITDA for the year. This marks a pivotal step towards our long-term profitability and underscores our commitment to delivering value. |
Posted at 05/2/2024 11:30 by brynos KROMEK GROUP PLCReleased 10:17:36 05 February 2024 RNS Number : 0345C Kromek Group PLC 05 February 2024 5 February 2024 Kromek Group plc ("Kromek" or the "Company" or the "Group") Conversion of £1.5m of Convertible Loan Notes Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that two holders of the convertible loan notes ("Loan Notes") issued in August 2022 have elected to convert them into new ordinary shares of 1 penny each in the Company ("Ordinary Shares") at conversion prices of 6.3 pence and 7.1 pence, per Ordinary Share. Including accrued interest, the Loan Note holders are converting £1,509,211 of debt into 23,639,520 new Ordinary Shares and accordingly these new Ordinary Shares have been issued and allotted by the board. The issue prices of 6.3 and 7.1 pence per new Ordinary Share represent the closing price of the Company's Ordinary Shares on AIM on 31 January 2024 and 2 February 2024, respectively, being the repayment date of the convertible loan note facilities. Application has been made for the 23,639,520 Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 8.00 a.m. on 9 February 2024 ("Admission"). The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued share capital will consist of 623,886,340 Ordinary Shares, none of which are held in treasury. Accordingly, the figure of 623,886,340 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules. |
Posted at 08/1/2024 20:31 by jaknife The recent boom in the number of shares is because of a convertible loan note. The last share conversion under the note was announced here:All is not what it seems and the directors have been deliberately deceptive on two levels. 1. Fixed Conversion Price The original RNS that announced the terms of the convertible is here: The conversion terms are described as: "The Loan Notes have a term of 18 months (with the Company having the option to extend the majority of the loan notes by three months), are senior in ranking and unsecured. The Loan Notes are convertible at investors option into ordinary shares in the capital of the Company ("Ordinary Shares") at 15 pence per Ordinary Share, representing a 30% premium to the mid-price of the Company's share price at close of business on 04 August 2022. The Loan Notes carry a coupon of 8% per annum and have a conversion date of 31 January 2024." And so you would be forgiven if you thought that the loan was convertible at 15p a share - it is not! The RNS then goes onto note: "The Loan Note holders have the right to elect to be repaid in whole or in part in Ordinary Shares at the lower of the closing mid-market price on the repayment date, and 15 pence per share." The reality of the wording is that this boils down to: "The Loan Note holders have the right to elect to be repaid in Ordinary Shares issued at the closing mid-market price on the repayment date." 2. Interest But there is a second more important deliberate deception that the directors are executing, which relates to the terms on which the interest on the loan is converted to shares. Specifically the directors have not disclosed in any formal RNS what the terms of conversion are for the interest element of the bond. It's not easy to work out what those terms are but we can work out that the terms are incredibly onerous. Going back to the recent conversion notice: it tells us that: ”Kromek … has issued and allotted 7,830,628 new ordinary shares in the Company ("Shares") at a conversion price of 5.11 pence per Share in order to settle the exercise of convertible loan notes and repayment of interest to certain convertible loan note holders … The Partial Conversion reduces the amount owing on the convertible notes by £261,000, with £2,579,000 remaining.” But if you do the simple calculation of £261,000 / 7,830,628 then you get to a conversion price of 3.33p!!! The explanation is that the RNS disclosure above only relates to principal and doesn’t include interest. Hence 5,107,632 shares have been issued at a price of 5.11p a share to repay the principal of £261,000 ( 5,107,632 shares x 5.11p = £261,000 ) and then a further 2,722,996 shares have been issued ( 7,830,628 - 5,107,632 ) to pay an undisclosed amount of interest at an undisclosed conversion price. Having different conversion terms for the principal and interest is a new trend with convertible loans, you can find similar convertible loans with both COPL and SOU that have different conversion terms between principal and interest. There’s no benefit to having these unusual terms other than to deceive shareholders into thinking that the deal is better than it actually is. JakNife |
Posted at 02/1/2024 13:08 by supernumerary Jak - they're right down the bottom of the page...This is just the first lot - not saying anything new... ------------- T Burley 26 DECEMBER, 2023 It's tiny and still loss-making after more than a decade in business and many funding rounds. It's not to a business, it's a customer charity transferring shareholders funds to them every day year after year. If it had scaled to billions or at least a few hundred million over these decades and was ... See more... Recommend (31) Andrew Lapping 26 DECEMBER, 2023 As a long suffering shareholder, try making a profit or get out of the way and let someone else try.The company has had numerous fundraisings, pre and post IPO, at ever decreasing values. Time to make a profit Recommend (15) Jonathon Cole 26 DECEMBER, 2023 The owner is part of the problem. He has persistently avoided investing and expanding to a greater scale required to boost profitability because he , like many science based entrepreneurs, he is afraid of / doesn’t understand dilution. They dont like losing control He should have raised more fund... See more... Recommend (12) S Evans 26 DECEMBER, 2023 Kromek has consistently come back to shareholders for funds at massive discounts, no way would the CEO have been able to obtain funds elsewhere if it was not public. As a shareholder I have been Distinctly unimpressed with the CEO and the board, the CEO continues to reward himself with a bloated sal... See more... Recommend (9) Ian Caswell 26 DECEMBER, 2023 What a terrible example. After 10 years floated only £17m turnover and a massive £7m loss. Pity the poor shareholders. Looks like a very poorly run company that will eventually change management or go bust. The market has reacted exactly the way it should to a rubbish business. Recommend (9) M Hedges 26 DECEMBER, 2023 What retail investors do understand is that when it comes to return on investment, the top line by itself is meaningless. A wafer thin gross margin and an eye watering loss at the operating level are of far more interest. An extremely high cash burn and constant dilution at lower and lower prices a... See more... Recommend (6) T Nicholson 26 DECEMBER, 2023 It sounds like a very clever business but if you’re not turning profit after a decade and having had multiple funding rounds, perhaps it is the business? Recommend (5) P Norton 26 DECEMBER, 2023 Blaming the market is shooting the messenger. Prices are information and the information this share price is telling you is that this is a rubbish company. If it were any good then a private buyer would have bought it or if the management back it, why not do a MBO? Of course the market isn’t always... See more... Recommend (4) Charles Mitchell 26 DECEMBER, 2023 Not only not profitable but they have had numerous fund raising. So no wonder the market values lowly. Interesting company, but would only buy on improved financial performance. Recommend (3) Bobbie Fish 26 DECEMBER, 2023 How do you value a business that is not making a profit which is in a fast moving technology world. You need to know about the competition and demand for its products. That’s a difficult valuation to make. Any valuation is on hope and the Kromek boss possibly a salesman is the last person to value ... See more... Recommended (0) James Robinson 26 DECEMBER, 2023 A poor comment which says everything. Look in the mirror Recommend (2) |
Posted at 02/1/2024 12:22 by jaknife This is the article. Perhaps it's my settings but I can't see any reader comments.==================== Kromek boss ‘might not have listed technology company on Aim’ Arnab Basu joins other technology bosses ‘frustrated Katie Prescott, Technology Business Editor Tuesday December 26 2023, 12.01am GMT, The Times Arnab Basu, the chief executive of Kromek, argues that technology businesses that require time and investment to grow are often ignored by UK investors in favour of short-term successes The boss of Kromek has said that with hindsight he might not have listed the scanning technology business on London’s junior stock market, adding his voice to those of other British technology chief executives who complain that the City lacks understanding of the sector. The share price of the Co Durham-based company, which designs and makes high-specification materials for security and medical imaging, has fallen by more than 90 per cent since it was listed on Aim in 2013, despite Kromek increasing its revenue and market share. Arnab Basu said it was “frustrating that the company’s value isn’t recognised”. The business, which celebrated its 20th anniversary this year, made £17 million of revenue in 2022, a 44 per cent rise from the year before. However, it has yet to make a profit, suffering an adjusted pre-tax loss of £7 million in 2023, down from £7.8 million the year before. About a third of its revenue is from the United States and a fifth from Britain. Kromek is covered by only one firm of City analysts — Cavendish, part of the finnCap Group. In July, after the company’s full-year results, Mark Brewer, finnCap’s director of research, wrote: “As the only independent supplier at scale of CZT [a semiconductor] for imaging systems, we believe there is substantial strategic value in Kromek that is not reflected in the current price.” Another London technology analyst, who does not follow the stock, said: “The low end of the Aim market capitalisation spectrum can be a trap in terms of low valuations. The company capitalises a lot of development costs and has been cashflow-negative for the past two years; improving profitability and turning cash-positive will be keys to getting a higher valuation.” Reflecting on its ten years as a public company, Basu, 50, said: “We have had a difficult time in the market, where the business has grown continuously but the value recognition has declined continuously. When you’re talking to retail investors, it must be very challenging for them to really understand a small, complex business. The relationship we had with private investors was much more interactive.” He argued that technology businesses that required time and investment to grow were often ignored in favour of short-term successes. “Hardware tech is still rare in the UK. And I think if you’re not in certain segments, understanding and the pool of investors within that is reasonably limited, which creates a pressure. Kromek’s story is shared by many compatriots in the tech market.” Basu moved to Newcastle from India for his degree and stayed in the city, spinning out his doctorate from Durham University into a business that supplies medical companies, airports and security services worldwide. Kromek developed a semiconductor technology and manufacturing process that goes into a range of applications, including creating Europe’s first liquid explosive detection system, and has won its first contract with the European Space Agency. Based in Sedgefield, the company employs 150 people with offices and manufacturing facilities in Pennsylvania and California. It supplies the US Department of Homeland Security and works with Darpa, the US defence agency, producing a portfolio of products for the military in radiation detection. Among the products in the pipeline, it is developing an airborne pathogen-testing system. The company works on detection in oncology, Alzheimer’s and cardiac processes and in the analysis of airborne diseases. Another area is radiation detection and Basu said it was looking at early warnings of biological or chemical weapons being used in public areas from cities to stadiums. |
Posted at 09/9/2023 22:26 by 33mick To put things in context and the short term (which it is )financing arrangements being hopefully sorted soon.Philips is a £4+ billion company that has been designing state of the art hi tech medical equipment and systems for longer than anyone's been alive reading this, if you look you will see Philips name has cropped up numerous times in Kmk past news releases and broker reports, they were working with kmk's US subsidiary EV Products who they took over 10 years ago. Analogic Corp a US privately owned company was sold 6 years ago for 1.1 bill dollars with est 500+ mil dollar annual revenues. Spectrum Dynamics the the first OEM to fully adopt Kmk's CZT into thier premier CT product are est to be valued at 50-100 mil dol. Plus the un-named new Asian 1.4 mil CZT SPECT imaging customer announced in May this year... these companies owners, CEO's, management ,design and development teams have thier money, reputations and future growth & profitability all firmly aligned and committed to using kmk's CZT gamma modules after years of collaboration in most cases. and I have no reason to doubt kmk's confident statements predicting the likes of Fuji medical, United Imaging and the others they are working with will not follow suit. But obviously AQC knows better! and presumably thinks all these bods have made a disastrous error of judgement. |
Posted at 09/5/2023 20:21 by aqc888 For some context;Pivotal year unfolding for Kromek - 18/1/22 Share price 14.5p Winners in an uncertain world - 16/5/22 Share price 9.7p Kromek’s record sales visibility is materially undervalued - 2/8/22 Share price 9.5p A biological detection winner - 11/22 Share price 8.75p This stock is about to turn world-leading technology into profit - 2/23 Analysts think this stock's share price will quadruple - 4/23 Share price 6.85p Buy into Kromek's £7.5mn open offer of new shares - today Share price 5p …. It goes back way further when share price was way way higher… “Don't worry about Kromek's revenue fall“ - 1/2019 Share price 26p |
Posted at 27/4/2023 15:17 by skyship Analysts think this stock's share price will quadrupleIt has announced a company-transforming seven-year agreement highlighting its bargain share price April 19, 2023.....By Simon Thompson Ground-breaking seven-year agreement with a Tier One OEM Agreement to develop next-generation CT detector technology Positive trading update Sedgefield-based Kromek (KMK:6.85p), a radiation detection technology company focused on the medical imaging and nuclear markets, has announced a company-transforming seven-year agreement with a top-tier original equipment manufacturer (OEM) to develop cadmium zinc telluride (CZT)-based detectors for the client’s advanced medical imaging scanners. Following a short development period, the agreement will transition into a longer commercial supply phase. The enhanced image quality associated with the technology could enable the earlier detection of diseases, such as heart disease and cancer, thereby improving patient outcomes and increasing efficiencies within healthcare settings. Analysts at Equity Development note that the medical imaging market is divided between computed tomography (CT) and single-photon emission CT (SPECT)-based products and is dominated by four tier-one suppliers: Phillips Medical Systems, Siemens Healthineers GmbH, Canon Medical Systems and GE Healthcare. House broker FinnCap estimates that the CT medical imaging scanner market was worth $6.7bn in 2022, with the tier-one suppliers controlling 85 to 90 per cent of the market. Market research company Market Data Forecast estimates that the CT scanner market could be worth $7.2bn in 2023, growing to $9bn by 2028, the implication being that this could be a $10bn market by 2030. Value of agreement to Kromek On this basis, FinnCap calculates that the CZT-based share of the CT scanner market could be worth $2bn in 2030, assuming the new technology scanners take a 20 per cent share of the total market, suggesting an addressable market opportunity of $300mn-$400mn for a tier-one supplier. This would imply revenue to Kromek of $64mn (£51mn) in 2030, generating $26mn (£20mn) of gross profit on a margin of 40 per cent and annual cash profit of £10mn-£15mn. Moreover, assuming the tier-one OEM converts 50 per cent of its scanners to CZT over a 10-year period, it implies that the agreement has a net present value (NPV) of £39mn-£59mn (9p to 14p a share) using discount rates of 10 to 15 per cent, respectively. In a more optimistic scenario in which the conversion rate rises to 75 per cent, the NPV of the agreement rises to £58mn-£87mn (13p to 20p a share), a hefty sum in relation to Kromek’s current market capitalisation of £28.8mn (6.85p). The strategic value of CZT to tier-one OEMs in their next-generation diagnostic imaging development was brought into sharp focus in September 2021 when Canon acquired Kromek’s rival Redlen Technologies for a valuation of $290mn, or a multiple of 20 to 33 times its annual revenue (£5.mn to £8.4mn) at the time. Kromek is now the only independent developer and producer of CZT-based detection systems. Equity Development has a read-across implied valuation for Kromek’s medical imaging division of £247mn (57p), or 8.5 times its current market capitalisation, based on a multiple of 25 times 2023-24 revenue estimates of £9.9mn for the unit. |
Posted at 10/8/2022 03:36 by ark87 The shareprice was down until IC tipped it (again). Unfortunately as you can see from KMK share price performance since inception (51p to to 14p over 9 years) will be short lived unless some game changing news is on horizon which at this point seems doubtful. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
